APLT:NSD-Applied Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.77

Change

+1.04 (+5.27)%

Market Cap

USD 0.44B

Volume

0.11M

Average Target Price

USD 44.00 (+111.84%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017

Company Website : http://www.appliedtherapeutics.com

Address : 545 Fifth Avenue, New York, NY, United States, 10017

Employees : 22

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 57.39

Short Ratio : 11.64

52 Week Low : 13.58

Shorted Shares : 1,551,642

200 Day Moving Average : 22.91

Shorted Shares Previous Month : 1,567,069

50 Day Moving Average : 22.17

Shares Held By Insiders : 238.83%

Short Percentage : 7.00%

Shares Held by Institutions : 71.47%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

 USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

 USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

 USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

 USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

 USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

 USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

 USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

 USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

 USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

 USD21.44B 47.64 35.20

ETFs Containing APLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.63% 9% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.63% 9% F 7% F
Trailing 12 Months  
Capital Gain -58.72% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.72% 4% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 58.48% 82% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.48% 82% B- 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 114.33% 19% F 9% F
Risk Adjusted Return 51.15% 79% C+ 72% C-
Market Capitalization 0.44B 52% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.31 59% F 39% F
Price / Cash Flow Ratio -12.22 58% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -131.51% 20% F 8% F
Return on Invested Capital -188.26% 10% F 4% F
Return on Assets -68.16% 7% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.64 9% F 5% F
Short Percent 11.30% 27% F 19% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector